Questions and answers 14May2026.xlsx
XLSX spreadsheet 13 KB Posted
- Attached to
- Portable Patient Transport System (PPTS) Final
- Solicitation number
- W911QY-26-S-PPTS-01
About this file
This is a Questions and Answers (Q&A) document for the Portable Patient Transport System (PPTS) Pre-Solicitation. The file contains responses to inquiries submitted by interested offerors regarding Call for Solutions (CFS) Number W911QY-26-S-PPTS-01, issued by U.S. Army Contracting Command-Aberdeen Proving Ground (ACC-APG), Natick Contracting Division on March 12, 2026. The CFS was issued under 10 U.S.C. 4022 authority against Army Open Solicitation W9128Z-25-S-A002 using Broad Agency Announcement (BAA) authority and seeks prototype solutions for a portable patient transport system. The Government intends to award multiple Prototype Other Transaction (OT) Agreements to offerors whose Solution Briefs are determined most advantageous based on stated evaluation criteria. The original question submission deadline was March 26, 2026 at 1700 Eastern Time, with questions to be submitted via email to designated Government Points of Contact in a single consolidated submission. This Q&A document, dated May 14, 2026, reflects answers provided after the initial question period and represents clarifications or responses to issues identified during the solicitation process.
The document serves as a clarification tool for potential offerors preparing Solution Briefs in response to the CFS. All communications regarding the competition are required to be submitted in writing exclusively to identified Government POCs, with unauthorized contact with other Government personnel potentially constituting an Organizational Conflict of Interest. Offerors are expected to review both this Q&A document and the referenced attachments, including the Statement of Objectives and Final Draft Call for Solutions, to fully understand requirements prior to submission.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Final Call for Solution PPTS (20May2026).docx | DOCX document | |
| Final Call for Solution PPTS (19May2026).docx | DOCX document | |
| Attachment 0002 PPTS Capabilities Assertion Matrix.xlsx | XLSX spreadsheet | |
| Updated PPTS Questions and Answers 15MAY2026.xlsx | XLSX spreadsheet | |
| Final AOS Statement of Objectives PPTS (14May2026).docx | DOCX document | |
| Final Call for Solution PPTS (14May2026).docx | DOCX document | |
| Questions and answers PPTS.xlsx | XLSX spreadsheet | |
| CPE CBRND Industry Day_BCIS-PPTS-SIS_1-1 Attendeees_18MAR26.pdf | ||
| Final Draft Call for Solution PPTS 12MAR2026..docx | DOCX document | |
| AOS Statement of Objectives PPTS_Final Draft (2026-03-12)..docx | DOCX document |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Sheet1
| Program | Question (from Q&A) | Answer (from Q&A) |
| PPTS | What is the distance between glove ports based on? | SOO, Table 2: "The PPTS glove ports that comprise a glove port pair shall have a center-to-center distance of no less than 33 cm and no greater than 43 cm" |
| PPTS | What is the rationale behind the number of glove ports? | SOO, Table 2: "The PPTS shall have fourteen total individual glove ports that are arranged in pairs... one pair... at the patient’s head... one pair... on either side... near the patient’s head... one pair... on either side... near the patient’s torso... one pair... on either side... near the patient’s feet." |
| PPTS | What is the difference between transport pouch vs pass through port? | SOO, Table 2: Defines. Pouch is transfer of items in and out of the system while maintaining negative pressure in the system. Port is more for transfer of cabling. |
| PPTS | Could the Government clarify the clinical rationale behind the 14-port desired requirement...? | SOO, Table 2: The 14-glove port requirement is listed under "Desired Requirements," not "Threshold Requirement." |
| PPTS | What types of large items does the DoW intend to transfer through the transfer pouch? | SOO, Table 2: "The PPTS transfer pouch shall be sized to accommodate the passing of items up to 8 inches by 12 inches. (e.g.: Food, water bottle, medication, absorbant pads, patient comfort items) |
| General | What is required for Berry amendment compliance? | This is a statutory requirement. See, 10 U.S.C. § 4862" |
| General | What if our initial deliverable is non-Berry compliant, with the promise that our final version will be? | SOO, Section 2.2.6: This section requires documentation and detailing of any non-compliant items but does not explicitly forbid them. However, the overall emphasis on testing and a single, final design implies that changes post-testing are highly discouraged. It is in the best interest of the government for the Prototypes to be Berry Compliant... replication of this testing is an unacceptable cost... |
| General | What kind of data rights are required? | SOO, Section 2.2.5: "The Government’s strong preference is for Unlimited Rights... Proposals that provide less than Government Purpose Rights (GPR)... may be evaluated negatively..." |
| PPTS | Is the requirement for the filter to be located outside the system vs. inside? | SOO, Table 2: Under Desired Requirements for Filtration Efficiency: "The PPTS intake filter shall be located outside of the containment enclosure. The PPTS exhaust filter shall be located outside of the containment enclosure." |
| PPTS | Would the Government confirm whether EN1822 H14 certification is an acceptable equivalent to NIOSH P-100...? | The requirement for the exhaust filter is HEPA-equivalent filtration performance of 99.97% or greater at 0.3 microns, the SOO explicitly states that NIOSH P-100 is a threshold certification requirement. This allows other certifications that also meet NIOSH criteria. |
| PPTS | Can the DoW clarify the intended functional use of the pass‑through ports? Would alternative interface designs that achieve equivalent clinical functionality be acceptable? | We will consider alternative interface designs. Examples of functional pass-through items include vent tubes, IV lines, patient care devices, EKG wires |
| PPTS | If a solution can demonstrate equivalent bilateral access with fewer glove ports, would the DoW consider compliance based on demonstrated operational effectiveness rather than a fixed number of ports? | See threshold requirement |
| PPTS | Could the Government provide or reference the applicable NSN or specifications for the stanchion systems in these platforms so offerors can demonstrate compatibility in their Solution Briefs? | The government does not have the NSN, however specifications are provided at: https://www.coemed.org/files/stanags/03_AMEDP/AMedP-2.1_EDA_V1_E_2040.pdf |
| PPTS | Is Berry amendment required? | Yes. Must be able to identify where raw material come from. |
| PPTS | Why is affordability only being considered as a part of Segment 2 selections and not Segment 1 selections? | It will be considered at all phase of the OTA |
| PPTS | Could the Government clarify how pre-existing government-funded IP interacts with the Unlimited Rights preference in Section F? | “The Government’s strong preference is for Unlimited Rights for all technical data, software, and associated intellectual property developed under this effort.” |
| PPTS | Additionally, could the Government clarify how IP assertions that protect commercially developed elements of the design will be weighed against the Unlimited Rights preference in the evaluation? | Legal response: Review the criteia as wriiten. “The Government’s strong preference is for Unlimited Rights for all technical data, software, and associated intellectual property developed under this effort.” |
| PPTS | What are the temperature ranges during operation? 120 degrees seems high. | Operating temperatures are listed in the SOO and associated MIL-STD. |
| PPTS | Specifically, is a Solution Brief acceptable if the offeror demonstrates a credible Phase III path to FDA clearance even if clearance has not yet been initiated? | The solution briefs for FDA marketing authorization and full airworthiness are required by the end of Phase III. The Offerors RSP must demonstrate a credible approach to meeting the project's core objectives. Draft Interface Control Document (ICD); submission of the FDA 510(k) clearance request and performer's status with the FDA 510(k) clearance process. |
_x000D_&1#&"Aptos"&10&K000000 DISTRIBUTION: DoW COMMUNITY ONLY https://www.coemed.org/files/stanags/03_AMEDP/AMedP-2.1_EDA_V1_E_2040.pdf
File details come from the government source that posted it. Updated .